The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

CMS has published its final rule for Medicare Advantage and Part D in 2026, outlining a series of regulatory updates aimed at ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8705 ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability. Read why MCK stock is a ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as ...